WEBINAR ON DEMAND
Duration: 1 hour

Over the last twenty years Fragment-based drug design (FBDD) has emerged as a prominent strategy. Yet FBDD is not without challenges, including commercial libraries often hampered by excessively sized fragments.

Recently new assaying techniques have emerged that push the boundaries of what’s possible with fragment screening, offering collections specifically tailored to biophysical screening. In this webinar, two respected industry authorities reveal how next-generation FBDD fragment screening can assist biophysical researchers more efficiently: 

• Identify and prioritize the best fragment hits
• Compress hit-to-lead campaign times
• Reduce research cost and raise lead throughput

SPEAKERS  

Dr. Andrew Scott
Head of Bioassay Development and Screening
Concept Life Sciences

Dr. Thomas Pesnot
Medicinal Chemistry Research Leader
Concept Life Sciences

​

Dr. Matilda Bingham
VP of Science
Concept Life Sciences